RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced that it has completed a license expansion agreement with GtreeBNT for the rights to RGN-137, RegeneRx's topical gel formulation of thymosin beta 4 (Tß4), in Europe, S. Korea, Japan, Canada and Australia.

Titan Pharmaceuticals, Inc. announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for its ropinirole implant intended for treatment of the signs and symptoms of Parkinson's disease.

Cmed has announced it will present its encapsia® clinical data suite at Mobile in Clinical Trials and DPharm: Disruptive Innovations to Advance Clinical Trials 2017.

Blake Insomnia Therapeutics Inc. , a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to announce it has submitted its clinical trial application for Phase II clinical testing to Health Canada.

Symic Bio, a biopharmaceutical company developing novel matrix regulators,announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee.

Achieve Life Sciences, Inc. a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced initiation of the Cytisine Clinical Development Program.